English

Mersana Therapeutics, Inc.

EDGAR

MRSN Current report (8-K) · filed 2026-01-06

Annual consolidated revenue for 2024: about USD 40.5M, using the latest reported figures. The previous period, 2023, was about USD 36.86M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

11 million USD

2025 Q3 · USD

Exact inputs and evidence

Revenue: 11009000 USD Source

Net margin

-68.13%

2025 Q3 · %

Exact inputs and evidence

Net Income: -7500000 USD Source
Revenue: 11009000 USD Source

Operating cash flow

-3.19 million USD

2025 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -55120000 USD Source
Operating Cash Flow: -51928000 USD Source

Free cash flow

-3.19 million USD

2025 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -55120000 USD Source
Operating Cash Flow: -51928000 USD Source
Capital Expenditure: 0 USD Source
Capital Expenditure: 0 USD Source

Cash and cash equivalents: 56.4 million USD 2025-09-30 Source
Exact value

56391000 USD
Long-term debt including current maturities: 20.1 million USD 2024-03-31 Source
Exact value

20098000 USD
Shares outstanding: 5 million shares 2025-09-30 Source
Exact value

4998500 shares

Reported share-count change

-95.93% · -118 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

122866659 shares · 2024-09-30· Source
4998500 shares · 2025-09-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-01-06.

Financial data available through: 2024-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2024-12-31
operating income: No compatible figures in this window
Net income: 7 of 11 periods available· newest 2024-12-31
Operating cash flow: 7 of 11 periods available· newest 2024-12-31
Capital expenditure: 7 of 11 periods available· newest 2024-12-31
Total assets: 6 of 11 periods available· newest 2024-12-31
Total liabilities: 6 of 11 periods available· newest 2024-12-31
Current assets: 6 of 11 periods available· newest 2024-12-31
Current liabilities: 6 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2024-12-31
Long-term debt including current maturities: 4 of 11 periods available· newest 2023-12-31
Shares outstanding: 6 of 11 periods available· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+9.9%

Prior period

USD 36.86 million

2023-01-01 – 2023-12-31
Current period

USD 40.5 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

40497000 − 36855000 = 3642000 USD

36855000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
40497000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Mersana Therapeutics, Inc. · 2024-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Year-over-year change in Revenue: 3642000 USD Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 40497000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1331254 Filing: 000162828025009246 Input fundies:Revenue: 36855000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1332157 Filing: 000162828025009246
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 102.5 million

Prior period

−USD 171.7 million

2023-01-01 – 2023-12-31
Current period

−USD 69.2 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-69200000 − -171700000 = 102500000 USD

-171700000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-69200000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Mersana Therapeutics, Inc. · 2024-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Year-over-year change in Net income: 102500000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -69200000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1568877 Filing: 000162828025009246 Input fundies:NetIncome: -171700000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1569063 Filing: 000162828025009246
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 86.54 million

Prior period

−USD 168.88 million

2023-01-01 – 2023-12-31
Current period

−USD 82.34 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-82340000 − -168882000 = 86542000 USD

-168882000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-82340000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Mersana Therapeutics, Inc. · 2024-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Year-over-year change in Operating cash flow: 86542000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -82340000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1507829 Filing: 000162828025009246 Input fundies:OperatingCashFlow: -168882000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1508485 Filing: 000162828025009246
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-93.9%

Prior period

USD 2.17 million

2023-01-01 – 2023-12-31
Current period

USD 132,000

2024-01-01 – 2024-12-31

Exact inputs and evidence

132000 − 2168000 = -2036000 USD

2168000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
132000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Mersana Therapeutics, Inc. · 2024-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Year-over-year change in Capital expenditure: -2036000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 132000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1515196 Filing: 000162828025009246 Input fundies:CapitalExpenditure: 2168000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1515759 Filing: 000162828025009246
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue USD 40.5 million 100% of revenue
Operating costs Derived Unavailable An input is unavailable.
Operating income Unavailable An input is unavailable.
Tax, interest and other Derived Unavailable An input is unavailable.
Net income −USD 69.2 million −171% of revenue

Cash

Operating cash flow −USD 82.34 million −203% of revenue
Capital expenditure USD 132,000 0.3% of revenue
Free cash flow Derived −USD 82.47 million −204% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2018 Not shown: operating income or net income is not reported.
2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2018 2018-01-01 – 2018-12-31	10594000	Unavailable	Unavailable	Unavailable	-64257000	-56586000 Derived	Source 2018-01-01 – 2018-12-31: 10594000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -64257000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -55216000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 1370000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	42123000	Unavailable	Unavailable	Unavailable	-28208000	-68349000 Derived	Source 2019-01-01 – 2019-12-31: 42123000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -28208000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -67744000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 605000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	828000	Unavailable	Unavailable	Unavailable	-88000000	-75169000 Derived	Source 2020-01-01 – 2020-12-31: 828000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -88000000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -74696000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 473000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	43000	Unavailable	Unavailable	Unavailable	-170100000	-140636000 Derived	Source 2021-01-01 – 2021-12-31: 43000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -170100000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -139988000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 648000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	26581000	Unavailable	Unavailable	Unavailable	-204200000	-51560000 Derived	Source 2022-01-01 – 2022-12-31: 26581000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -204200000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -49363000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 2197000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	36855000	Unavailable	Unavailable	Unavailable	-171700000	-171050000 Derived	Source 2023-01-01 – 2023-12-31: 36855000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -171700000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -168882000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 2168000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	40497000	Unavailable	Unavailable	Unavailable	-69200000	-82472000 Derived	Source 2024-01-01 – 2024-12-31: 40497000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -69200000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -82340000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 132000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 40.5M 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Revenue	10594000	Revenue: 10594000 Open source
20192019-12-31	Revenue	42123000	Revenue: 42123000 Open source
20202020-12-31	Revenue	828000	Revenue: 828000 Open source
20212021-12-31	Revenue	43000	Revenue: 43000 Open source
20222022-12-31	Revenue	26581000	Revenue: 26581000 Open source
20232023-12-31	Revenue	36855000	Revenue: 36855000 Open source
20242024-12-31	Revenue	40497000	Revenue: 40497000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

9.9% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Year over year	No prior comparable period	Revenue: 10594000 Open source
20192019-12-31	Year over year	297.6%	Revenue: 42123000 Open source Revenue: 10594000 Open source
20202020-12-31	Year over year	-98%	Revenue: 828000 Open source Revenue: 42123000 Open source
20212021-12-31	Year over year	-94.8%	Revenue: 43000 Open source Revenue: 828000 Open source
20222022-12-31	Year over year	61,716.3%	Revenue: 26581000 Open source Revenue: 43000 Open source
20232023-12-31	Year over year	38.7%	Revenue: 36855000 Open source Revenue: 26581000 Open source
20242024-12-31	Year over year	9.9%	Revenue: 40497000 Open source Revenue: 36855000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Net margin -170.9% 2024

Free cash flow margin -203.6% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2018-12-31	Operating margin	Not reported	Revenue: 10594000 Open source
2019-12-31	Operating margin	Not reported	Revenue: 42123000 Open source
2020-12-31	Operating margin	Not reported	Revenue: 828000 Open source
2021-12-31	Operating margin	Not reported	Revenue: 43000 Open source
2022-12-31	Operating margin	Not reported	Revenue: 26581000 Open source
2023-12-31	Operating margin	Not reported	Revenue: 36855000 Open source
2024-12-31	Operating margin	Not reported	Revenue: 40497000 Open source
20182018-12-31	Net margin	-606.5%	Net Income: -64257000 Open source Revenue: 10594000 Open source
20192019-12-31	Net margin	-67%	Net Income: -28208000 Open source Revenue: 42123000 Open source
20202020-12-31	Net margin	-10,628%	Net Income: -88000000 Open source Revenue: 828000 Open source
20212021-12-31	Net margin	-395,581.4%	Net Income: -170100000 Open source Revenue: 43000 Open source
20222022-12-31	Net margin	-768.2%	Net Income: -204200000 Open source Revenue: 26581000 Open source
20232023-12-31	Net margin	-465.9%	Net Income: -171700000 Open source Revenue: 36855000 Open source
20242024-12-31	Net margin	-170.9%	Net Income: -69200000 Open source Revenue: 40497000 Open source
20182018-12-31	Free cash flow margin	-534.1%	Revenue: 10594000 Open source Operating Cash Flow: -55216000 Open source Capital Expenditure: 1370000 Open source
20192019-12-31	Free cash flow margin	-162.3%	Revenue: 42123000 Open source Operating Cash Flow: -67744000 Open source Capital Expenditure: 605000 Open source
20202020-12-31	Free cash flow margin	-9,078.4%	Revenue: 828000 Open source Operating Cash Flow: -74696000 Open source Capital Expenditure: 473000 Open source
20212021-12-31	Free cash flow margin	-327,060.5%	Revenue: 43000 Open source Operating Cash Flow: -139988000 Open source Capital Expenditure: 648000 Open source
20222022-12-31	Free cash flow margin	-194%	Revenue: 26581000 Open source Operating Cash Flow: -49363000 Open source Capital Expenditure: 2197000 Open source
20232023-12-31	Free cash flow margin	-464.1%	Revenue: 36855000 Open source Operating Cash Flow: -168882000 Open source Capital Expenditure: 2168000 Open source
20242024-12-31	Free cash flow margin	-203.6%	Revenue: 40497000 Open source Operating Cash Flow: -82340000 Open source Capital Expenditure: 132000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -82.3M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Operating cash flow	-55216000	Operating Cash Flow: -55216000 Open source
20192019-12-31	Operating cash flow	-67744000	Operating Cash Flow: -67744000 Open source
20202020-12-31	Operating cash flow	-74696000	Operating Cash Flow: -74696000 Open source
20212021-12-31	Operating cash flow	-139988000	Operating Cash Flow: -139988000 Open source
20222022-12-31	Operating cash flow	-49363000	Operating Cash Flow: -49363000 Open source
20232023-12-31	Operating cash flow	-168882000	Operating Cash Flow: -168882000 Open source
20242024-12-31	Operating cash flow	-82340000	Operating Cash Flow: -82340000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -82.5M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Free cash flow	-56586000	Operating Cash Flow: -55216000 Open source Capital Expenditure: 1370000 Open source
20192019-12-31	Free cash flow	-68349000	Operating Cash Flow: -67744000 Open source Capital Expenditure: 605000 Open source
20202020-12-31	Free cash flow	-75169000	Operating Cash Flow: -74696000 Open source Capital Expenditure: 473000 Open source
20212021-12-31	Free cash flow	-140636000	Operating Cash Flow: -139988000 Open source Capital Expenditure: 648000 Open source
20222022-12-31	Free cash flow	-51560000	Operating Cash Flow: -49363000 Open source Capital Expenditure: 2197000 Open source
20232023-12-31	Free cash flow	-171050000	Operating Cash Flow: -168882000 Open source Capital Expenditure: 2168000 Open source
20242024-12-31	Free cash flow	-82472000	Operating Cash Flow: -82340000 Open source Capital Expenditure: 132000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

106.6% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2018-12-31	Liabilities / assets	Not reported	No source recorded
20192019-12-31	Liabilities / assets	27.2%	Total Liabilities: 29223000 Open source Total Assets: 107541000 Open source
20202020-12-31	Liabilities / assets	16.6%	Total Liabilities: 45312000 Open source Total Assets: 273399000 Open source
20212021-12-31	Liabilities / assets	40.9%	Total Liabilities: 84370000 Open source Total Assets: 206111000 Open source
20222022-12-31	Liabilities / assets	72.5%	Total Liabilities: 242283000 Open source Total Assets: 334340000 Open source
20232023-12-31	Liabilities / assets	83.7%	Total Liabilities: 189156000 Open source Total Assets: 226060000 Open source
20242024-12-31	Liabilities / assets	106.6%	Total Liabilities: 154172000 Open source Total Assets: 144663000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.19× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2018-12-31	Current assets / current liabilities	Not reported	No source recorded
20192019-12-31	Current assets / current liabilities	4.21×	Current Assets: 101326000 Open source Current Liabilities: 24070000 Open source
20202020-12-31	Current assets / current liabilities	8.62×	Current Assets: 258580000 Open source Current Liabilities: 30003000 Open source
20212021-12-31	Current assets / current liabilities	3.97×	Current Assets: 188898000 Open source Current Liabilities: 47523000 Open source
20222022-12-31	Current assets / current liabilities	3.49×	Current Assets: 319219000 Open source Current Liabilities: 91533000 Open source
20232023-12-31	Current assets / current liabilities	3.36×	Current Assets: 214057000 Open source Current Liabilities: 63637000 Open source
20242024-12-31	Current assets / current liabilities	2.19×	Current Assets: 136904000 Open source Current Liabilities: 62458000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 64.26 million Exact value Exact value: -64257000 USD 2018-01-01 – 2018-12-31: -64257000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Mersana Therapeutics, Inc. · 2018-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Net Income: -64257000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -64257000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828021003370/mrsn-20201231.htm#1365921 Filing: 000162828021003370 The citation records this snapshot. The page link may show a newer release later.	−USD 55.22 million Exact value Exact value: -55216000 USD 2018-01-01 – 2018-12-31: -55216000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Mersana Therapeutics, Inc. · 2018-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Operating Cash Flow: -55216000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -55216000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828021003370/mrsn-20201231.htm#1281852 Filing: 000162828021003370 The citation records this snapshot. The page link may show a newer release later.	USD 1.37 million Exact value Exact value: 1370000 USD 2018-01-01 – 2018-12-31: 1370000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Mersana Therapeutics, Inc. · 2018-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Capital Expenditure: 1370000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1370000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828021003370/mrsn-20201231.htm#1292537 Filing: 000162828021003370 The citation records this snapshot. The page link may show a newer release later.	−USD 56.59 million Calculation and evidence -55216000 − 1370000 USD Exact free cash flow: -56586000 USD 2018-01-01 – 2018-12-31: -55216000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 1370000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Mersana Therapeutics, Inc. · 2018-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Free cash flow: -56586000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -55216000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828021003370/mrsn-20201231.htm#1281852 Filing: 000162828021003370 Input fundies:CapitalExpenditure: 1370000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828021003370/mrsn-20201231.htm#1292537 Filing: 000162828021003370 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 28.21 million Exact value Exact value: -28208000 USD 2019-01-01 – 2019-12-31: -28208000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Mersana Therapeutics, Inc. · 2019-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Net Income: -28208000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28208000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828022004101/mrsn-20211231.htm#1454031 Filing: 000162828022004101 The citation records this snapshot. The page link may show a newer release later.	−USD 67.74 million Exact value Exact value: -67744000 USD 2019-01-01 – 2019-12-31: -67744000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Mersana Therapeutics, Inc. · 2019-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Operating Cash Flow: -67744000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -67744000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828022004101/mrsn-20211231.htm#1365546 Filing: 000162828022004101 The citation records this snapshot. The page link may show a newer release later.	USD 605,000 Exact value Exact value: 605000 USD 2019-01-01 – 2019-12-31: 605000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Mersana Therapeutics, Inc. · 2019-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Capital Expenditure: 605000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 605000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828022004101/mrsn-20211231.htm#1376286 Filing: 000162828022004101 The citation records this snapshot. The page link may show a newer release later.	−USD 68.35 million Calculation and evidence -67744000 − 605000 USD Exact free cash flow: -68349000 USD 2019-01-01 – 2019-12-31: -67744000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 605000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Mersana Therapeutics, Inc. · 2019-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Free cash flow: -68349000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -67744000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828022004101/mrsn-20211231.htm#1365546 Filing: 000162828022004101 Input fundies:CapitalExpenditure: 605000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828022004101/mrsn-20211231.htm#1376286 Filing: 000162828022004101 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 88 million Exact value Exact value: -88000000 USD 2020-01-01 – 2020-12-31: -88000000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Mersana Therapeutics, Inc. · 2020-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Net Income: -88000000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -88000000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828023005376/mrsn-20221231.htm#1516015 Filing: 000162828023005376 The citation records this snapshot. The page link may show a newer release later.	−USD 74.7 million Exact value Exact value: -74696000 USD 2020-01-01 – 2020-12-31: -74696000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Mersana Therapeutics, Inc. · 2020-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Operating Cash Flow: -74696000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -74696000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828023005376/mrsn-20221231.htm#1427366 Filing: 000162828023005376 The citation records this snapshot. The page link may show a newer release later.	USD 473,000 Exact value Exact value: 473000 USD 2020-01-01 – 2020-12-31: 473000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Mersana Therapeutics, Inc. · 2020-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Capital Expenditure: 473000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 473000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828023005376/mrsn-20221231.htm#1438138 Filing: 000162828023005376 The citation records this snapshot. The page link may show a newer release later.	−USD 75.17 million Calculation and evidence -74696000 − 473000 USD Exact free cash flow: -75169000 USD 2020-01-01 – 2020-12-31: -74696000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 473000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Mersana Therapeutics, Inc. · 2020-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Free cash flow: -75169000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -74696000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828023005376/mrsn-20221231.htm#1427366 Filing: 000162828023005376 Input fundies:CapitalExpenditure: 473000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828023005376/mrsn-20221231.htm#1438138 Filing: 000162828023005376 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 170.1 million Exact value Exact value: -170100000 USD 2021-01-01 – 2021-12-31: -170100000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Mersana Therapeutics, Inc. · 2021-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Net Income: -170100000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -170100000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828024007407/mrsn-20231231.htm#1467626 Filing: 000162828024007407 The citation records this snapshot. The page link may show a newer release later.	−USD 139.99 million Exact value Exact value: -139988000 USD 2021-01-01 – 2021-12-31: -139988000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Mersana Therapeutics, Inc. · 2021-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Operating Cash Flow: -139988000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -139988000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828024007407/mrsn-20231231.htm#1408610 Filing: 000162828024007407 The citation records this snapshot. The page link may show a newer release later.	USD 648,000 Exact value Exact value: 648000 USD 2021-01-01 – 2021-12-31: 648000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Mersana Therapeutics, Inc. · 2021-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Capital Expenditure: 648000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 648000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828024007407/mrsn-20231231.htm#1415847 Filing: 000162828024007407 The citation records this snapshot. The page link may show a newer release later.	−USD 140.64 million Calculation and evidence -139988000 − 648000 USD Exact free cash flow: -140636000 USD 2021-01-01 – 2021-12-31: -139988000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 648000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Mersana Therapeutics, Inc. · 2021-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Free cash flow: -140636000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -139988000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828024007407/mrsn-20231231.htm#1408610 Filing: 000162828024007407 Input fundies:CapitalExpenditure: 648000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828024007407/mrsn-20231231.htm#1415847 Filing: 000162828024007407 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 204.2 million Exact value Exact value: -204200000 USD 2022-01-01 – 2022-12-31: -204200000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Mersana Therapeutics, Inc. · 2022-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Net Income: -204200000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -204200000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1569253 Filing: 000162828025009246 The citation records this snapshot. The page link may show a newer release later.	−USD 49.36 million Exact value Exact value: -49363000 USD 2022-01-01 – 2022-12-31: -49363000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Mersana Therapeutics, Inc. · 2022-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Operating Cash Flow: -49363000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -49363000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1509142 Filing: 000162828025009246 The citation records this snapshot. The page link may show a newer release later.	USD 2.2 million Exact value Exact value: 2197000 USD 2022-01-01 – 2022-12-31: 2197000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Mersana Therapeutics, Inc. · 2022-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Capital Expenditure: 2197000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2197000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1516353 Filing: 000162828025009246 The citation records this snapshot. The page link may show a newer release later.	−USD 51.56 million Calculation and evidence -49363000 − 2197000 USD Exact free cash flow: -51560000 USD 2022-01-01 – 2022-12-31: -49363000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 2197000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Mersana Therapeutics, Inc. · 2022-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Free cash flow: -51560000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -49363000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1509142 Filing: 000162828025009246 Input fundies:CapitalExpenditure: 2197000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1516353 Filing: 000162828025009246 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 171.7 million Exact value Exact value: -171700000 USD 2023-01-01 – 2023-12-31: -171700000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Mersana Therapeutics, Inc. · 2023-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Net Income: -171700000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -171700000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1569063 Filing: 000162828025009246 The citation records this snapshot. The page link may show a newer release later.	−USD 168.88 million Exact value Exact value: -168882000 USD 2023-01-01 – 2023-12-31: -168882000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Mersana Therapeutics, Inc. · 2023-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Operating Cash Flow: -168882000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -168882000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1508485 Filing: 000162828025009246 The citation records this snapshot. The page link may show a newer release later.	USD 2.17 million Exact value Exact value: 2168000 USD 2023-01-01 – 2023-12-31: 2168000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Mersana Therapeutics, Inc. · 2023-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Capital Expenditure: 2168000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2168000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1515759 Filing: 000162828025009246 The citation records this snapshot. The page link may show a newer release later.	−USD 171.05 million Calculation and evidence -168882000 − 2168000 USD Exact free cash flow: -171050000 USD 2023-01-01 – 2023-12-31: -168882000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 2168000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Mersana Therapeutics, Inc. · 2023-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Free cash flow: -171050000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -168882000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1508485 Filing: 000162828025009246 Input fundies:CapitalExpenditure: 2168000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1515759 Filing: 000162828025009246 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 69.2 million Exact value Exact value: -69200000 USD 2024-01-01 – 2024-12-31: -69200000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Mersana Therapeutics, Inc. · 2024-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Net Income: -69200000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -69200000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1568877 Filing: 000162828025009246 The citation records this snapshot. The page link may show a newer release later.	−USD 82.34 million Exact value Exact value: -82340000 USD 2024-01-01 – 2024-12-31: -82340000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Mersana Therapeutics, Inc. · 2024-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Operating Cash Flow: -82340000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -82340000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1507829 Filing: 000162828025009246 The citation records this snapshot. The page link may show a newer release later.	USD 132,000 Exact value Exact value: 132000 USD 2024-01-01 – 2024-12-31: 132000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Mersana Therapeutics, Inc. · 2024-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Capital Expenditure: 132000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 132000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1515196 Filing: 000162828025009246 The citation records this snapshot. The page link may show a newer release later.	−USD 82.47 million Calculation and evidence -82340000 − 132000 USD Exact free cash flow: -82472000 USD 2024-01-01 – 2024-12-31: -82340000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 132000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Mersana Therapeutics, Inc. · 2024-12-31 Mersana Therapeutics, Inc. (edgar:1442836) Free cash flow: -82472000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1442836?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -82340000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1507829 Filing: 000162828025009246 Input fundies:CapitalExpenditure: 132000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm#1515196 Filing: 000162828025009246 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

66 filings · 2,849 latest values · 2,849 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001442836, 1442836, MRSN, edgar:1442836

Also known as MERSANA THERAPEUTICS INC, MERSANA THERAPEUTICS, INC., Mersana Therapeutics, Inc., Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc.

Latest quarter

Revenue

Net margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation